As of December 31, 2024, cash and marketable securities were $127 million as compared to $152 million as of December 31, 2023, providing the Company with an anticipated cash runway into 2027. During 2024, $45 million of net cash was used in operating activities, and this was offset by $18 million of cash raised through the companys ATM in the first quarter of 2024.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMPX:
- Compass Therapeutics initiated with a Buy at Guggenheim ahead of BTC data
- Compass Therapeutics initiated with a Buy at Guggenheim
- Compass Therapeutics initiated with an Overweight at Piper Sandler
- Buy Rating for Compass Therapeutics Driven by Promising Tovecimig Results and Strategic Pipeline
- Two new option listings on February 11th
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue